肝细胞癌患者仑伐替尼诱导的掌跖感觉丧失性红斑综合征的风险因素：一项回顾性研究。

Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective study.

机构信息

Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Funabashi, Japan.

Toho University Ohashi Medical Center, Meguro-ku, Japan.

出版信息

Cancer Med. 2024 Aug;13(16):e70065. doi: 10.1002/cam4.70065.

DOI:10.1002/cam4.70065

PMID:39190576

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11348904/

Abstract

AIM

Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.

METHODS

This was a single-centre, retrospective study of patients with HCC who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.

RESULTS

Overall, 75 patients with HCC were enrolled. LEN-induced PPES was found in 48.0% (36/75 patients). In these patients, alkaline phosphatase (ALP), γ-Glutamyl transpeptidase (γ-GTP) and monocytes (MONO) were significantly high (ALP: p = 1.32 × 10, γ-GTP: p = 4.25 × 10 and MONO: p = 0.013). The cut off values of ALP, γ-GTP and MONO for LEN-induced PPES were estimated at 573 U/L, 89 U/L, and 310 counts/μL, respectively. In the multivariate analysis, γ-GTP and MONO were independent risk factors for LEN-induced PPES.

CONCLUSIONS

High γ-GTP and high MONO were risk factors for LEN-induced PPES.

摘要

目的

甲磺酸仑伐替尼（LEN）是一种口服酪氨酸激酶抑制剂，用于治疗多种癌症，包括肝细胞癌（HCC）。用 LEN 治疗 HCC 会导致不良反应发生率非常高。本研究旨在通过分析接受 LEN 治疗的 HCC 患者的临床实验室数据，调查 LEN 诱导的掌跖红斑感觉迟钝综合征（PPES）的发生率及其与患者人口统计学特征的关系。

方法

这是一项单中心、回顾性研究，纳入了 2018 年 4 月 19 日至 2020 年 9 月 30 日期间接受 LEN 治疗的 HCC 患者。观察期为 LEN 给药前 1 周至给药后 1 个月。

结果

共有 75 例 HCC 患者入组。发现 48.0%（36/75 例）的患者出现 LEN 诱导的 PPES。在这些患者中，碱性磷酸酶（ALP）、γ-谷氨酰转肽酶（γ-GTP）和单核细胞（MONO）显著升高（ALP：p=1.32×10，γ-GTP：p=4.25×10，MONO：p=0.013）。LEN 诱导的 PPES 的 ALP、γ-GTP 和 MONO 的截断值分别估计为 573 U/L、89 U/L 和 310 个/μL。在多变量分析中，γ-GTP 和 MONO 是 LEN 诱导的 PPES 的独立危险因素。